Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.

doi:10.1007/s12072-021-10158-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.

Hepatology international - 1 Apr 2021

Liu Chen-Hua, Chen Po-Yueh, Chen Jyh-Jou, Lo Ching-Chu, Su Wei-Wen, Tseng Kuo-Chih, Liu Chun-Jen, Huang Chia-Sheng, Huang Ke-Jhang, Yang Sheng-Shun, Peng Cheng-Yuan, Tsai Ming-Chang, Kao Wei-Yu, Chang Chi-Yang, Shih Yu-Lueng, Fang Yu-Jen, Chen Chi-Yi, Lee Pei-Lun, Huang Jow-Jyh, Su Pei-Yuan, Tseng Chi-Wei, Hung Chien-Ching, Chang Chung-Hsin, Huang Yi-Jie, Lai Hsueh-Chou, Chang Chun-Chao, Lee Fu-Jen, Hsieh Tsai-Yuan, Kao Jia-Horng

Abstract excerpt

BACKGROUND: Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) for East Asian patients with chronic hepatitis C virus (HCV) infection and compensated liver disease are limited. We evaluated the performance of SOF/VEL for 12 weeks for HCV-infected patients with compensated liver disease in a large real-world cohort in Taiwan. METHODS: Between July 2019 and March 2020, 1880...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 4 or More Rings

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Taiwan

Source

Open in PubMed

Identifiers

PMID: 33677787
DOI: 10.1007/s12072-021-10158-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.PMID 33677787Read ↗

[Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].Semantic proximity Read ↗

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.Semantic proximity Read ↗

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.Semantic proximity Read ↗

[A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].Semantic proximity Read ↗

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.Semantic proximity Read ↗

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.Semantic proximity Read ↗

Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Semantic proximity Read ↗

Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.